Indications: CSM. It is recommended that mild CSM be treated in the short term (3 years) either with surgical decompression or with nonoperative therapy (prolonged immobilization in a stiff cervical collar, "low-risk" activity modification or bed rest, and antiinflammatory medications) based on patient preference (quality of evidence, Class II; strength of recommendation, C). More severe CSM should be treated with surgical decompression with benefits being maintained a minimum of 5 years and as long as 15 years postoperatively (quality of evidence, Class III; strength of recommendation, D).
Rationale
The purpose of this review was to use an evidencebased approach to examine whether patients benefit from anterior surgical intervention in the setting of mild versus severe cervical myelopathy. Cervical myelopathy is often classified as mild, moderate, or severe depending on the degree of impairment in arm and leg function. As cervical spondylosis increases in severity, it may cause compression of the neural elements, resulting in myelopathy. Compression may often occur anteriorly at the level of the disc space. In general, severe myelopathy has been considered a strong indication for surgical therapy; 7 however, the question arises whether mild cervical myelopathy with anterior compression is best treated surgically or with nonoperative measures. 5 
Search Criteria
We conducted a computerized search of the Cochrane Database and of the National Library of Medicine between 1966 and 2007 using MeSH headings. The search headings included the following terms: "cervical vertebrae," "outcome assessment," "cervical spondylosis," "myelopathy," "cervical spondylotic myelopathy," "controlled clinical trial," "spinal osteophytosis," and "spinal cord disease." The total number of citations was 1689 when terms were combined. One study (a systematic review) was found in the Cochrane database. Of these articles, we analyzed only those in the English language. We reviewed the abstracts of these citations and selected applicable articles. We reviewed the references cited in the qualifying articles to gather any other applicable manuscripts published between 1966 and 2007. Five references were found that provided potentially high-quality evidence (Table 1) .
Scientific Foundation

Mild Cervical Myelopathy
The studies described by Bednarik et al. 1 and Kadanka and colleagues 3 appear to concern the same group of patients. However, the Bednarik et al. study included electrophysiological data in addition to clinical outcome data. For the purpose of this analysis, these studies will be discussed together. In total, the authors examined 61 patients with CSM. Forty-nine had mild CSM, with mJOA scale scores > 12, and 12 patients were considered to have severe CSM, with mJOA scale scores ≤ 12. All patients were younger than 75 years of age. The randomized trial examined the group of 49 patients with milder symptoms, 22 of whom were randomized to surgery, and 27 to nonoperative therapy. Nonoperative therapy included activity modification (rest or "low risk" activities), antiinflammatory medications, and cervical immobilization. Follow-up was over 24 months and included analysis of mJOA scale scores, a timed 10-m walk, and video analysis of ADLs. 3 Patients with mild or moderate myelopathy were allocated by coin toss to each treatment arm. Age and sex ratios were similar between the 2 groups. There was a slight imbalance in mJOA scores and a greater imbalance in gait scores, which favored groups allocated to nonoperative treatment. 2 Specifically, there was a significant difference in 10-m walk times in the control group. These differences suggested that the treatment allocation might have been biased. In this study, the 18 patients underwent surgical decompression via an anterior approach compared to only 4 who received the posterior approach. Clinically, mJOA scale scores and 10-m walk times improved significantly at 6 months in the nonoperative group compared to the surgical group. However, these differences were not evident at 12 and 24 months. The authors concluded that operative and nonoperative management of mild-to-moderate CSM yielded similar results at 2 years. The subgroup of 12 patients with severe disability (mean mJOA scale score of 9.5) showed significant improvement after surgical intervention (mean mJOA scale score 10.9 at 2 years postoperatively). 1, 3 Because of its small size, this study was powered to have a minimal detectable difference in mJOA scale score of 1.7. With pretreatment mJOA scores starting at ~ 14 out of a possible 18, the level of improvement would have to be 42% (1.7/4.0) for the study to have a detectable a difference; this raises the likelihood of a Type II error. Although these studies were randomized and the outcome assessment was blinded, it appeared that concealment of allocation was biased toward the nonoperative group. 2 Furthermore, the large standard deviation in the demographic factors in each group suggests inappropriately small sample sizes. Accordingly, these studies were considered to provide Class II evidence regarding the treatment of patients with CSM.
Kadanka et al. 4 reported on 66 patients, of whom 33 underwent surgery and 33 received nonoperative therapy. Outcomes were assessed using the mJOA scale, 10-m walk times, and video ADLs. Outcome assessors were blinded to group during mJOA and video ADL assessment, and outcomes were stratified into nonresponders, responders, and very good responders. Patients in both groups showed improvement. The authors stratified outcome and observed that older patients did better with conservative therapy, whereas surgery was better if the transverse area of the spinal cord was < 70 mm 2 . This study was graded Class II due to the lack of allocation concealment. Furthermore, the mJOA scores began at 14 in the surgery group and 15 in the nonoperative group, essentially creating a ceiling effect. The duration of symptoms was longer in the surgical group (3 years vs 1 year). 4 One systematic review by Fouyas et al. 2 in the Cochrane database examined surgical treatment of myeloradiculopathy. The authors found 2 studies that met inclusion criteria. One study was on the surgical treatment of radiculopathy and the other was on treatment of CSM. The second study was undertaken by Bednarik et al. 1 and was described above. As we mentioned, the study by Bednarik and colleagues was graded Class II due to difficulties in balancing the groups with respect to mJOA scale scores and because of the lack of concealment of allocation. In their systematic review, Fouyas et al. 2 corroborated the inconsistencies in assembling and balancing the groups preoperatively.
Sampath et al. 6 reported on 62 patients with CSM who were enrolled as part of a larger 503-patient study.
The study physicians recommended surgery in 31 of the 62 patients while the remaining 31 patients underwent nonoperative therapy. Surgery was a mixture of anterior and posterior approaches. Only 43 of the 62 patients underwent follow-up, 23 in the medically treated group, and 20 in the surgical group. Neurological outcome was assessed using the Neurological Rating Assessment, which was a validated, reliable scale. In this study, surgical patients improved on "Neurological Rating Assessment" and stayed the same with regard to video-assessed ADLs. Neurological and ADL assessments showed that the patients who did not undergo surgery had worsened functionally in both categories. Because of the poor followup and ad hoc subgroup analysis, this study was graded Class III. 6 
Severe Cervical Myelopathy
In their study detailed above, Bednarik et al. 1 also described an observational group of 12 patients with severe myelopathy (mJOA score < 12). The patients in this group had an average mJOA score of 9.5; all underwent surgical decompression, via an anterior approach in 7. This group had a statistically significant improvement in mJOA scale scores beginning at 6 months and continuing through 24 months. Simultaneous improvement in electrophysiological function also occurred in these patients. 1 Because there was no nonoperative group for patients with mJOA scores < 12, this study was graded Class III with respect to surgical treatment of severe CSM. 1 Wada and colleagues 7 examined a group of patients with severe CSM over a 15-year period after surgery. These authors compared cervical corpectomy to lamin- Sy stematic review of surgery for cervical radiculopathy & myelopathy. Inclusion & exclusion criteria included. 2 studies were found that met criteria. Only 1 study dealt w/ surgery for myelopathy (Bednarik et al.) .
Th e systematic review found equivalency between surgery & nonoperative management over a 3-yr FU period. However, the authors noted that group allocation was not blinded & bias of preop paring favored the nonoperative group (better mJOA scores & 10-m walk times).
II Th e systematic review was graded Class II because the study examining surgery for myelopathy itself was graded Class II because of biases in the stratification of groups that were duly noted. oplasty for the treatment of severe CSM. Similar to the Bednarik study, there was no nonoperative control group. Twenty-three patients (average age 52 years with symptoms of 15 months' duration) underwent subtotal corpectomy and reconstruction. The average preoperative JOA score was 7.9 (out of a maximum of 17). The average JOA scores improved to 13.3 at 1 year, 13.9 at 5 years, and finally 13.4 at an average follow-up of 15 years. This study was scored as Class III because there was not a nonoperative control group. In addition, it was not evident whether outcome assessors were blinded.
Summary
Currently, there exists no Class I evidence to assess the efficacy of anterior surgery for mild or severe CSM. Class II studies have indicated improvement with both operative and nonoperative therapy for mild CSM. Controlled clinical trials comparing the 2 approaches in the setting of mild CSM have been flawed but indicated equivalency between surgery and nonoperative therapy in 1 group of studies derived from the same patient population (Class II), and greater benefit for surgery in a different trial that was part of a larger trial (Class III). Current evidence (Class II) suggests that mild CSM (mJOA scale score > 12) may be managed with surgery or nonoperative management over the short term (3 years). However, more severe CSM (mJOA scale score < 12) appears to respond more readily to surgery (Class III).
The shortcoming of any evidence-based approach is that the recommendations are only as strong as the underlying studies. Although the studies systematically reviewed in this article indicate a stable time course for patients with mild symptoms, several questions and concerns arise. First, an mJOA score of 12 may not necessarily be considered mild disease as it was in the underlying studies. In general, patients with an mJOA score of 12 have a moderate impairment in gait, bladder, or hand function (motor or sensory), or a combination of disabilities. Clinical deterioration from this point may be ominous in terms of the functional ability. Secondly, even if CSM is stable without surgical correction for 3 years, what about the probability of deterioration after 3 years? If the underlying problem is not corrected, deterioration after 3 years may be an issue. Once again, the limits of the evidence-based approach are that it cannot specifically answer this question if it has not been studied. Other systematic reviews in this series on laminectomy, laminoplasty, laminectomy and fusion, and anterior surgery indicate clinical improvement after surgery over several years' duration. This segues into the third issue: the absence of Level 1 evidence on this subject and how to ameliorate that deficiency. It is probably impossible to design a practical study that would provide Level 1 evidence; however, Level 2 evidence could potentially be gained from a well-structured case-control series based on a prospective registry.
Key Issues
It is imperative that further investigation of CSM be undertaken using larger, multicenter, controlled clinical trials to examine the specific benefit, if any, that surgery has in the treatment of mild CSM and to determine its overall benefit in severe CSM.
